Navigation Links
Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
Date:8/19/2007

PALO ALTO, Calif., Aug. 15 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that new guidelines, developed jointly by the American College of Cardiology Foundation and the American Heart Association and published in this week's issue of Circulation, state that, "ranolazine may be safely administered for symptom relief after UA/NSTEMI."

Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates. The product has not been determined by regulatory authorities to be safe and effective for any other use.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to treatment guidelines, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. siRNA Design Guidelines
2. Federal and global guidelines on stem cell research offer a level playing field
3. With ethics guidelines, political consensus emerging on stem-cell research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2017)... ... September 14, 2017 , ... DrugDev ... biotech at the third annual DrugDev Summit, November 7-8, 2017 in Philadelphia, PA. ... most progressive clinical research leaders for best practice case studies, keynote presentations, lively ...
(Date:9/14/2017)... Australia (PRWEB) , ... September 14, 2017 , ... ... first viscoelastic Freedom Lumbar Disc case in Australia. Dr. Steven Yang completed the ... pain as a result of a degenerative lumbar disc at level L5-S1. The ...
(Date:9/14/2017)... ... September 14, 2017 , ... Cambridge Semantics , ... announced that its Anzo Smart Data Lake has been named a KMWorld ... solutions that help organizations succeed in surpassing their knowledge management goals. KMWorld searches ...
(Date:9/12/2017)... , ... September 12, 2017 , ... ... and highly scalable cloud-based platform for ambulatory patient monitoring and clinical trial support, ... Advance Clinical Trials conference in Boston. , Launched in 2005, PhysIQ leverages ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):